VFY — Vitrafy Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- AU$215.61m
- AU$189.81m
- AU$0.17m
Annual cashflow statement for Vitrafy Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.628 | 1.83 | 2.05 | 5.2 | 3.78 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -5.87 | -4.96 | -6.79 | -8.8 | -15.8 |
| Capital Expenditures | -0.486 | -0.09 | -0.013 | -0.002 | -0.537 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | -10.1 | -5 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | -0.486 | -0.09 | -0.013 | -10.1 | -5.54 |
| Financing Cash Flow Items | 0 | -0.103 | -0.639 | -3.25 | -2.03 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.058 | 5.8 | 11.5 | 32 | 27.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -6.42 | 0.758 | 4.69 | 13.1 | 6.58 |